Literature DB >> 20160028

An oncogenic role for ETV1 in melanoma.

Judit Jané-Valbuena1, Hans R Widlund, Sven Perner, Laura A Johnson, Aurora C Dibner, William M Lin, Alissa C Baker, Rosalynn M Nazarian, Krishna G Vijayendran, William R Sellers, William C Hahn, Lyn M Duncan, Mark A Rubin, David E Fisher, Levi A Garraway.   

Abstract

Copy gains involving chromosome 7p represent one of the most common genomic alterations found in melanomas, suggesting the presence of "driver" cancer genes. We identified several tumor samples that harbored focal amplifications situated at the peak of common chromosome 7p gains, in which the minimal common overlapping region spanned the ETV1 oncogene. Fluorescence in situ hybridization analysis revealed copy gains spanning the ETV1 locus in >40% of cases, with ETV1 amplification (>6 copies/cell) present in 13% of primary and 18% of metastatic melanomas. Melanoma cell lines, including those with ETV1 amplification, exhibited dependency on ETV1 expression for proliferation and anchorage-independent growth. Moreover, overexpression of ETV1 in combination with oncogenic NRAS(G12D) transformed primary melanocytes and promoted tumor formation in mice. ETV1 overexpression elevated microphthalmia-associated transcription factor expression in immortalized melanocytes, which was necessary for ETV1-dependent oncogenicity. These observations implicate deregulated ETV1 in melanoma genesis and suggest a pivotal lineage dependency mediated by oncogenic ETS transcription factors in this malignancy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20160028      PMCID: PMC2846410          DOI: 10.1158/0008-5472.CAN-09-3092

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

Review 1.  Molecular biology of the Ets family of transcription factors.

Authors:  Tsuneyuki Oikawa; Toshiyuki Yamada
Journal:  Gene       Date:  2003-01-16       Impact factor: 3.688

2.  HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1.

Authors:  D G Bosc; B S Goueli; R Janknecht
Journal:  Oncogene       Date:  2001-09-27       Impact factor: 9.867

3.  A putative second cell-derived oncogene of the avian leukaemia retrovirus E26.

Authors:  D Leprince; A Gegonne; J Coll; C de Taisne; A Schneeberger; C Lagrou; D Stehelin
Journal:  Nature       Date:  1983 Nov 24-30       Impact factor: 49.962

4.  DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma.

Authors:  R A Bailly; R Bosselut; J Zucman; F Cormier; O Delattre; M Roussel; G Thomas; J Ghysdael
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

5.  Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf.

Authors:  Basem S Goueli; Ralf Janknecht
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

6.  Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer.

Authors:  Karin G Hermans; Hetty A van der Korput; Ronald van Marion; Dennis J van de Wijngaart; Angelique Ziel-van der Made; Natasja F Dits; Joost L Boormans; Theo H van der Kwast; Herman van Dekken; Chris H Bangma; Hanneke Korsten; Robert Kraaij; Guido Jenster; Jan Trapman
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

7.  (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway.

Authors:  Christine A Pratilas; Barry S Taylor; Qing Ye; Agnes Viale; Chris Sander; David B Solit; Neal Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-27       Impact factor: 11.205

Review 8.  Ets proteins in biological control and cancer.

Authors:  Tien Hsu; Maria Trojanowska; Dennis K Watson
Journal:  J Cell Biochem       Date:  2004-04-01       Impact factor: 4.429

9.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

10.  Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.

Authors:  Jennifer C King; Jin Xu; John Wongvipat; Haley Hieronymus; Brett S Carver; David H Leung; Barry S Taylor; Chris Sander; Robert D Cardiff; Suzana S Couto; William L Gerald; Charles L Sawyers
Journal:  Nat Genet       Date:  2009-04-26       Impact factor: 38.330

View more
  68 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  Delving into somatic variation in sporadic melanoma.

Authors:  Vijay Walia; Euphemia W Mu; Jimmy C Lin; Yardena Samuels
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

Review 3.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

4.  Cancer: Oncogenes in context.

Authors:  Michael C Heinrich; Christopher L Corless
Journal:  Nature       Date:  2010-10-14       Impact factor: 49.962

5.  Metastatic melanoma with striking adenocarcinomatous differentiation illustrating phenotypic plasticity in melanoma.

Authors:  John R Jalas; Swapna Vemula; Vladimir Bezrookove; Philip E Leboit; Jeffry P Simko; Boris C Bastian
Journal:  Am J Surg Pathol       Date:  2011-09       Impact factor: 6.394

6.  Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells.

Authors:  Peter C Hollenhorst; Mary W Ferris; Megan A Hull; Heejoon Chae; Sun Kim; Barbara J Graves
Journal:  Genes Dev       Date:  2011-10-15       Impact factor: 11.361

Review 7.  The ETS family of oncogenic transcription factors in solid tumours.

Authors:  Gina M Sizemore; Jason R Pitarresi; Subhasree Balakrishnan; Michael C Ostrowski
Journal:  Nat Rev Cancer       Date:  2017-04-28       Impact factor: 60.716

Review 8.  ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors.

Authors:  Sangphil Oh; Sook Shin; Ralf Janknecht
Journal:  Biochim Biophys Acta       Date:  2012-03-08

9.  Cancer: Trouble upstream.

Authors:  E Elizabeth Patton; Lea Harrington
Journal:  Nature       Date:  2013-03-21       Impact factor: 49.962

10.  ETS variant 1 regulates matrix metalloproteinase-7 transcription in LNCaP prostate cancer cells.

Authors:  Sook Shin; Sangphil Oh; Seayoon An; Ralf Janknecht
Journal:  Oncol Rep       Date:  2012-10-16       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.